Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer

Figures & data

Figure 1. Flow chart of study participants.

Table 1. MDM2 SNP55 genotype distribution and risk estimates for ovarian and endometrial cancer.

Cases/controls	Genotype SNP55, n (%)			Dominant model		Recessive model
				OR (95% CI) SNP55	Fisher exact p Value	OR (95% CI) SNP55	Fisher exact p Value
	CC	CT	TT	TT + CT vs CC		TT vs CT + CC
Healthy control	638 (34.3)	871 (46.9)	349 (18.8)	–	–	–	–
Ovarian cancers	468 (35.1)	627 (47.1)	237 (17.8)	0.97 (0.83–1.12)	0.65	0.94 (0.78–1.12)	0.49
Non-serous	151 (36.7)	184 (44.8)	76 (18.5)	0.90 (0.72–1.13)	0.36	0.98 (0.75–1.30)	0.94
Serous	316 (34.4)	442 (48.1)	161 (17.5)	1.00 (0.85–1.18)	1.00	0.92 (0.75–1.13)	0.44
High grade serous	168 (35.2)	229 (48.0)	80 (16.8)	0.96 (0.78–1.19)	0.75	0.87 (0.67–1.14)	0.32
Endometrial cancer	479 (35.1)	641 (47.0)	243 (17.8)	0.97 (0.83–1.12)	0.65	0.94 (0.78–1.12)	0.52
Endometrioid	362 (35.2)	475 (46.2)	191 (18.6)	0.96 (0.82–1.13)	0.65	0.99 (0.81–1.20)	0.92
Serous papillary	37 (31.4)	61 (51.7)	20 (16.9)	1.15 (0.77–1.71)	0.55	0.88 (0.54–1.45)	0.72

OR: Odds ratio; CI: Confidence interval; n: number of individuals.

Figure 2. Impact of MDM2 SNP55 on ovarian and endometrial cancers risk. Forest plots illustrating the effect (odds ratio; OR) of SNP55 (dominant model) on risk of ovarian- and endometrial cancer in (A) overall cancer patients and (B) in patients harbouring the MDM2 SNP309TT genotype. Dot size indicate sample size (number of cases) and horizontal whiskers indicate 95% confidence interval for the OR estimate.

Table 2. MDM2 SNP55 genotype distribution among carriers of the SNP309TT and TG genotypes.

	Genotype SNP55, n (%)			Dominant model		Recessive model
				OR (95% CI) SNP55	Fisher exact p Value	OR (95% CI) SNP55	Fisher exact p Value
	CC	CT	TT	TT + CT vs CC		TT vs CT + CC
Within SNP309TT
Healthy controls	71 (9.7)	310 (42.5)	349 (47.8)	–	–	–	–
Ovarian cancers	61 (11.5)	234 (44.1)	236 (44.4)	0.83 (0.58–1.19)	0.35	0.87 (0.70–1.09)	0.25
Non-serous	19 (11.7)	67 (41.4)	76 (46.9)	0.81 (0.47–1.39)	0.47	0.97 (0.69–1.36)	0.86
Serous	41 (11.1)	167 (45.4)	160 (43.5)	0.86 (0.57–1.29)	0.46	0.84 (0.65–1.08)	0.18
High grade serous	24 (12.4)	90 (46.4)	80 (41.2)	0.76 (0.47–1.25)	0.29	0.77 (0.56–1.06)	0.11
Endometrial cancer	81 (14.7)	236 (42.8)	235 (42.6)	0.63 (0.45–0.88)	0.01	0.81 (0.65–1.01)	0.07
Endometrioid	60 (14.4)	172 (41.3)	184 (44.2)	0.64 (0.44–0.92)	0.02	0.87 (0.68–1.10)	0.27
Serous papillary	6 (12.5)	22 (45.8)	20 (41.7)	0.75 (0.31–1.84)	0.46	0.78 (0.43–1.41)	0.46
Within SNP309TG
Healthy controls	314 (35.9)	561 (64.1)	0 (0.0)	–	–	–
Ovarian cancers	211 (34.9)	392 (64.9)	1 (0.2)	1.04 (0.84–1.30)	0.74	na	na
Non-serous	72 (38.1)	117 (61.9)	0 (0.0)	0.91 (0.66–1.26)	0.56	na	na
Serous	139 (33.6)	274 (66.2)	1 (0.2)	1.11 (0.87–1.42)	0.45	na	na
High grade serous	67 (32.7)	138 (67.3)	0 (0.0)	1.15 (0.84–1.59)	0.42	na	na
Endometrial cancer	210 (34.8)	394 (65.2)	0 (0.0)	1.05 (0.85–1.31)	0.70	na	na
Endometrioid	160 (35.2)	294 (64.8)	0 (0.0)	1.03 (0.81–1.30)	0.86	na	na
Serous papillary	15 (28.8)	37 (71.2)	0 (0.0)	1.38 (0.75–2.56)	0.37	na	na

OR: odds ratio; CI: confidence interval; n: number of individuals; na: not applicable.